Patent · US Active

Fused tricyclic compounds as Raf kinase inhibitors

US9273046B2 · kind B2 · utility

6Cited by
1References
9Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 31, 2011
Grant dateMar 1, 2016
Priority date—
Expiry dateDec 31, 2031

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D519/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.